Select Medication

*In clinical trials lasting 68 and 72 weeks involving participants without diabetes who had a BMI of 30 or higher, or a BMI of 27 with an associated weight-related condition, the use of Wegovy (2.4 mg) and Zepbound (15 mg) resulted in significant weight loss. Participants using Wegovy saw an average weight reduction of 15%, and those using Zepbound experienced a 20% decrease, both in conjunction with lifestyle modifications such as diet and exercise. In contrast, participants who only made dietary and exercise changes without these medications experienced weight losses of 2.4% and 3.1%, respectively. It should be noted that no direct clinical trials have been conducted on the compound forms of these medications; the results are extrapolated from the effects of the active ingredients, Semaglutide and Tirzepatide.